<DOC>
	<DOC>NCT01842581</DOC>
	<brief_summary>The purpose of the study is to evaluate if Rifaximin alone or Rifaximin plus Lactulose delays the onset of hepatic encephalopathy (HE) in cirrhotic subjects who have had a previous episode of HE.</brief_summary>
	<brief_title>The Safety/Efficacy Of Rifaximin With/Without Lactulose In Subjects With A History Of Recurrent Hepatic Encephalopathy</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Lactulose</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Male and nonpregnant, nonlactating females &gt;/= 18 years In remission from demonstrated overt HE Have had one or more episodes of overt HE associated with cirrhosis in the last 6 months Subject has a close family member or other personal contact who is familiar with the subject's HE and can provide continuing oversight to the subject and is willing to perform as caregiver during the conduct of the trial HIV History of Tuberculosis infection Chronic respiratory insufficiency Current infection and receiving antibiotics Renal insufficiency requiring dialysis Active spontaneous bacterial peritonitis infection Intestinal obstruction or inflammatory bowel disease Active malignancy within the last 5 years Current GI bleeding or has a history of a GI hemorrhage (within last 3 months Anemia Scheduled to receive a liver transplant within 1 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Liver Failure</keyword>
	<keyword>Hepatic Insufficiency</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>Brain Diseases</keyword>
	<keyword>Rifaximin</keyword>
	<keyword>Cirrhosis</keyword>
</DOC>